Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11396550 Methods of treating comprising administering anti-OX40L antibodies

Patent 11396550 was granted and assigned to Kymab on July, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Kymab

Current Assignee

Kymab

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11396550

Date of Patent

July 26, 2022

Patent Application Number

15661658

Date Filed

July 27, 2017

Patent Citations

‌

US Patent 10669342 Anti-OX40L antibodies and methods of treating graft versus host disease

‌

US Patent 10654935 Methods of treating SLE with anti-OX40L antibodies

Patent Citations Received

‌

US Patent 11753479 Nucleic acids encoding anti-OX40L antibodies

‌

US Patent 11773175 Antibodies, uses and methods

‌

US Patent 11779604 Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Patent Primary Examiner

‌

Phillip Gambel

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11396550 Methods of treating comprising administering anti-OX40L antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API